GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

New tests may show how much value a particular obese patient will get for a GLP-1 agonist prescription dollar.

I attended my high school reunion and had no anxiety about appearance,” Sarah gushed. “My new problem was graciously ...

Experimental weight-loss drug Retatrutide shows promise, helping obese adults lose up to 22% of their weight in 48 weeks.

The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...

Ozempic and Wegovy are two popular injectable medications for weight loss and diabetes. But what’s the difference?

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

How GLP-1 therapies could help build a healthier, more productive workforce—and what that would mean for how we live together ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo ...

A study in pigs has shown that the active ingredient in Ozempic and Wegovy directly boosts heart health, in addition to the ...

Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

Lilly’s offering is expected to surpass Novo’s Wegovy in the space, and, according to a report this week from GlobalData, it ...